Myxedema coma is the most severe, life-threatening form of hypothyroidism, in which a prolonged lack of thyroid hormone causes the body’s systems to slow to the point of organ failure, loss of consciousness, and dangerously low body temperature. Despite its name, not every patient is technically comatose at presentation, but the condition kills roughly a third or more of those who develop it, even with modern intensive care. It remains extremely rare, which paradoxically makes it more dangerous: most doctors will never see a case, and the diagnosis can be missed until it is nearly too late.
How Common Is It and Who Gets It
Myxedema coma is one of the rarest endocrine emergencies. A nationwide Japanese database study estimated the incidence at about one case per million people per year, and even that may overcount slightly because the study captured all suspected diagnoses in roughly 19 million hospital records.1PubMed Central. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan A broader systematic review pooling data from multiple countries arrived at an even lower figure, estimating roughly 0.12 cases per million per year.2PubMed Central. Myxedema coma: challenges and future directions, a systematic survey and review Either way, the condition is vanishingly uncommon in any single hospital.
The typical patient is an older woman. In the Japanese database, the average age was 77 and about two-thirds of patients were female.3PubMed Central. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan This skew makes sense because hypothyroidism itself is far more common in women and becomes more prevalent with age. Most patients who develop myxedema coma have a long-standing thyroid problem that was either undiagnosed or inadequately treated, and some push factor tips them over the edge.
Mortality remains stubbornly high. The Japanese analysis found that about 30% of patients died in the hospital, while the systematic review across multiple datasets put the overall death rate closer to 39%.4PubMed Central. Myxedema coma: challenges and future directions, a systematic survey and review Shock and multiple organ failure are the leading causes of death. Those numbers are far better than the historical mortality of over 80% reported before the 1960s, but they are still sobering for a condition that is, at its root, a hormone deficiency.5JAMA Internal Medicine. Treatment of Myxedema Coma With Intravenous Thyroxine
What Pushes Someone Over the Edge
People with untreated or undertreated hypothyroidism can survive in a chronically depleted state for years. What turns chronic hypothyroidism into myxedema coma is almost always an additional stressor that overwhelms the body’s already thin reserves. Winter cold is a classic trigger: most cases cluster in the colder months. In the Japanese database, admissions peaked during winter, and a tertiary-care study from India found that about two-thirds of patients presented during winter months.6PubMed Central. Predictors of outcome in myxoedema coma: a study from a tertiary care centre Because thyroid hormone is central to the body’s heat production, a hypothyroid patient exposed to cold weather faces a metabolic crisis their body literally cannot warm its way out of.
Infection is the other major precipitant. In the same tertiary-care series, sepsis was the accompanying condition in nearly three-quarters of patients.7PubMed Central. Predictors of outcome in myxoedema coma: a study from a tertiary care centre Pneumonia and urinary tract infections are among the most common culprits. Surgery, trauma, stroke, heart failure, and gastrointestinal bleeding can all serve as the tipping point as well. Certain medications are particularly risky for hypothyroid patients: sedatives, opioids, anesthetics, lithium, and amiodarone have all been linked to precipitating myxedema coma. Diuretic use appeared in over half of patients in one study, and it complicated the picture by masking the initial diagnosis and worsening electrolyte imbalances.8PubMed Central. Predictors of outcome in myxoedema coma: a study from a tertiary care centre
Where the Name Comes From
The word “myxedema” refers to a distinctive type of skin swelling. Unlike the pitting edema you see in heart failure, where pressing a finger into the shin leaves a dent, myxedema produces a firm, doughy swelling that does not pit with pressure.9PubMed Central. Thyroid hormone action on skin This happens because of a buildup of hyaluronic acid, a sugar-based molecule that draws and holds water in the skin and other tissues.10PubMed. Acid glycosaminoglycans in myxoedema When thyroid hormone drops, the body fails to clear these molecules normally. They accumulate in the skin, tongue, heart muscle, and skeletal muscles, pulling water into the tissue and producing swelling that looks puffy but feels rubbery rather than squishy.
Autopsy and biopsy studies have confirmed that hyaluronic acid concentrations are significantly elevated in the skin of untreated hypothyroid patients compared to healthy controls, and that this buildup has strong water-binding capacity, explaining the non-pitting quality.11Acta Endocrinologica. The effect of 1-thyroxine treatment on skin accumulation of acid glycosaminoglycans in primary myxoedema Tissue analysis of one severely hypothyroid patient found hyaluronic acid elevated in the tongue, heart muscle, skeletal muscles, and skin, but not uniformly in every organ.12PubMed. Acid glycosaminoglycans in myxoedema The swelling of the face, hands, and particularly the tongue (macroglossia) is often one of the first visible clues that something is wrong.
How the Body Shuts Down
Thyroid hormone acts as a metabolic thermostat for nearly every organ system. When levels crash severely enough, the slowdown cascades through the entire body at once. That is what makes myxedema coma so dangerous: it is not a single-organ emergency but a simultaneous multi-system failure.
Temperature and the Brain
Hypothermia is one of the hallmarks. Because thyroid hormone drives the cellular reactions that generate body heat, profoundly hypothyroid patients lose the ability to maintain a normal core temperature. Readings below 35°C (95°F) are common, and some patients present with temperatures in the low 80s Fahrenheit. The low body temperature itself impairs brain function, compounding the altered mental state that ranges from confusion and lethargy to frank unresponsiveness.13PubMed Central. Myxedema coma: a new look into an old crisis In clinical practice, a hypothermic patient with an unexplained change in mental status and no obvious infectious source should raise suspicion for myxedema coma, especially in an elderly woman.
Heart and Circulation
The heart slows and weakens. Thyroid hormone normally supports cardiac contractility, so a severe deficiency produces a sluggish heart with reduced output. This can progress to heart failure and even cardiogenic shock.14Journal of the American College of Cardiology. Myxedema Coma: A Rare Cause of Cardiogenic Shock and the Masking Effect of Dopamine Infusion On top of that, increased vascular permeability allows fluid to accumulate around the heart, producing pericardial effusions that further impair cardiac function.15PubMed Central. Myxedema Coma with Reversible Cardiopulmonary Failure: a Rare Entity in 21St Century Bradycardia, meaning a slow heart rate, is typical. Blood pressure tends to be low, and the heart may be unresponsive to the usual medications that would normally speed it up. Importantly, these cardiac changes can be reversible with thyroid hormone replacement, which is one of the reasons aggressive treatment matters.
Breathing
Respiratory failure is a frequent presenting feature and a leading cause of death. Multiple mechanisms contribute. The central respiratory drive, the brain’s signal telling the body to breathe, is blunted. The respiratory muscles themselves weaken due to the same metabolic slowdown affecting all skeletal muscle. And the upper airway can narrow: a swollen tongue (macroglossia) along with edema of the vocal cords and pharynx all obstruct airflow.16PubMed Central. A Case of Myxedema Coma and Respiratory Failure Pleural effusions, where fluid collects around the lungs, can further compress the lungs and worsen gas exchange.17Cureus. Hypercapnic Respiratory Failure Secondary to Myxedema Coma: A Case Report The result is rising carbon dioxide levels in the blood and falling oxygen, a combination that deepens unconsciousness in a vicious cycle. Studies have shown that the diminished breathing muscle strength in hypothyroid patients is reversible with thyroid hormone replacement, but the patient has to survive long enough to receive it.18Cureus. Hypercapnic Respiratory Failure Secondary to Myxedema Coma: A Case Report
Kidneys, Sodium, and the Gut
Low sodium (hyponatremia) is one of the most common lab abnormalities in myxedema coma. The kidneys lose their ability to excrete free water efficiently because of reduced blood flow, and the body inappropriately ramps up antidiuretic hormone, further diluting the blood’s sodium concentration.19PubMed Central. Severe Hyponatremia in a Patient with Myxedema Coma Severely low sodium itself can cause confusion, seizures, and coma, making it another layer in the downward spiral.
The gastrointestinal tract slows dramatically as well. Constipation is near-universal in severe hypothyroidism, but in myxedema coma the bowel can essentially stop moving altogether. In rare cases, the colon dilates massively without any physical blockage, a condition called acute colonic pseudo-obstruction. One reported case involved a 60-year-old woman whose bowel function returned only after thyroid hormone treatment was started; decompression and supportive measures alone were not enough.20PubMed Central. Ogilvie’s syndrome in a case of myxedema coma
How It Is Diagnosed
Diagnosing myxedema coma is tricky because no single test confirms it. The blood thyroid levels will obviously be abnormal, with very high TSH and very low free T4 in primary hypothyroidism, but those labs can take hours to come back, and in a critically ill patient there may not be time to wait. The clinical picture has to drive the decision. Doctors look for the characteristic constellation: hypothermia, altered consciousness, bradycardia, low blood pressure, respiratory depression, hyponatremia, and a history (even a vague one) of thyroid disease.
A diagnostic scoring system has been developed to standardize recognition. It grades abnormalities across thermoregulation, central nervous system function, cardiovascular signs, gastrointestinal symptoms, metabolic features, and whether a precipitating event is present. In the original study, a score of 60 or above correctly identified every confirmed case of myxedema coma, with full sensitivity and about 86% specificity.21PubMed. A diagnostic scoring system for myxedema coma Patients without myxedema coma typically scored between 25 and 50. The scoring system is not perfect, but it gives emergency and intensive care physicians a structured way to quantify their clinical suspicion rather than relying on gut instinct alone.
The Euthyroid Sick Syndrome Trap
One of the most dangerous diagnostic pitfalls involves a phenomenon where critical illness itself distorts thyroid lab results. When someone is very sick from any cause, their thyroid hormone levels often drop even though the thyroid gland is working normally. This condition, called euthyroid sick syndrome, can produce lab results that look deceptively like hypothyroidism. The reverse problem is also true: in rare cases, genuine myxedema coma can develop in a patient whose labs are muddied by concurrent euthyroid sick syndrome, making clinicians uncertain whether the thyroid numbers are real or just an artifact of being severely ill.22PubMed Central. The Development of Myxedema Coma in the Setting of Euthyroid Sick Syndrome: A Diagnostic Dilemma and Review of Management Strategies In patients with no prior history of thyroid disease, this overlap makes the diagnosis easy to miss entirely.
Treatment in the Intensive Care Unit
Myxedema coma requires immediate admission to an ICU. Treatment has three simultaneous pillars: replacing the missing thyroid hormone, supporting failing organ systems, and addressing whatever triggered the crisis.
Thyroid Hormone Replacement
The cornerstone is intravenous levothyroxine (synthetic T4). Current consensus guidelines recommend a large initial loading dose, typically in the range of 200 to 400 micrograms given intravenously, with lower doses for smaller patients, older patients, or those with heart disease, where the dose may be reduced to 100 to 200 micrograms.23European Thyroid Journal. Management of endocrine emergencies: joint consensus statement for management of myxoedema coma After the loading dose, daily replacement follows at a weight-based dose, reduced by about a quarter when given intravenously rather than by mouth.
Whether to add liothyronine (synthetic T3) remains a matter of debate. T3 is the more biologically active form of thyroid hormone, and in critically ill patients the normal conversion of T4 to T3 may be impaired. However, T3 acts faster and more powerfully, which raises the risk of triggering dangerous heart rhythms or a heart attack in an already fragile patient. A pragmatic approach suggested by recent consensus is to start with levothyroxine alone for the first 24 hours and add small doses of liothyronine only if the patient fails to improve, using particular caution in older patients or those with known heart disease.24European Thyroid Journal. Management of endocrine emergencies: joint consensus statement for management of myxoedema coma One published case demonstrated successful recovery using combination therapy of levothyroxine and liothyronine from the outset, with thyroid levels normalizing within days and no cardiac complications, though the authors treated a relatively younger patient.25Endocrine Journal. Successful treatment of myxedema coma with a combination of levothyroxine and liothyronine
Stress-Dose Steroids
Before or alongside thyroid hormone, patients typically receive intravenous corticosteroids (hydrocortisone). The reasoning is practical: some patients with myxedema coma also have adrenal insufficiency, and giving thyroid hormone speeds up the body’s metabolism of cortisol. If the adrenal glands cannot keep up, replacing the thyroid hormone without covering the cortisol deficit can trigger an adrenal crisis, which is itself life-threatening. Since there is usually no time to wait for adrenal testing results, empiric steroid coverage is standard practice.
Supportive Measures
Hypothermia is treated with passive rewarming, meaning warm blankets and a warm environment rather than aggressive active heating, which can cause blood vessels to dilate and worsen low blood pressure.26PubMed Central. A Cold Case: Myxedema Coma Patients who are hypotensive or heading toward respiratory failure may need vasopressors to maintain blood pressure and mechanical ventilation to keep breathing. Intubation in these patients can be hazardous: the swollen tongue and airway edema make the procedure technically difficult, and the drop in blood pressure that can follow induction of anesthesia is especially dangerous in someone whose cardiovascular system is already compromised. Vasopressors before intubation are sometimes necessary.27PubMed Central. A Cold Case: Myxedema Coma If infection triggered the crisis, targeted antibiotics are started immediately, and hyponatremia is corrected carefully to avoid its own neurological complications.
Newer Medication-Related Causes
An emerging concern is myxedema coma triggered by immune checkpoint inhibitors, the cancer immunotherapy drugs that have transformed treatment of melanoma and other cancers. These drugs work by releasing the brakes on the immune system, but a common side effect is thyroid inflammation (thyroiditis), which usually causes a brief period of overactive thyroid followed by permanent hypothyroidism. In most patients, the hypothyroidism is mild and manageable. Rarely, though, it can decompensate into full myxedema coma. One documented case involved a woman in her sixties receiving a combination of CTLA-4 and PD-1 inhibitors for advanced melanoma who developed life-threatening myxedema coma.28PubMed Central. Myxoedema coma caused by immunotherapy-related thyroiditis and enteritis As immunotherapy use expands across oncology, vigilant thyroid monitoring during treatment becomes more important. The risk is small in absolute terms, but it is worth being aware of because the transition from mild hypothyroidism to crisis can happen quickly if a second stressor hits.
How Mortality Has Changed Over Time
Before intravenous thyroid hormone preparations became available, myxedema coma was almost universally fatal. A 1964 review noted that although the condition had been recognized since 1879, more than 80% of patients treated between 1953 and 1961 died during treatment, and fewer than 60 cases had been published in English-language medical journals up to that point.29JAMA Internal Medicine. Treatment of Myxedema Coma With Intravenous Thyroxine The introduction of intravenous thyroxine and later triiodothyronine gave doctors tools they simply did not have before. Combined with advances in intensive care, better understanding of electrolyte management, and routine use of empiric steroids, the mortality rate has dropped by roughly half since those early decades.
That said, the improvement has plateaued in a frustrating way. The death rate has hovered between 25% and 40% in modern case series, and the systematic review estimate of around 39% suggests that current treatments, while much better than nothing, are not fully solving the problem.30PubMed Central. Myxedema coma: challenges and future directions, a systematic survey and review Part of the issue is the patient population itself: many are elderly with significant other health problems, and the precipitating events like sepsis carry their own high mortality. Part of it is diagnostic delay. By the time the diagnosis is made, multi-organ damage may already be advanced. Earlier recognition through wider awareness and tools like the clinical scoring system may be the most realistic path to further reducing deaths.
Why People With Known Hypothyroidism Still Develop It
One of the more perplexing aspects of myxedema coma is that many patients had a diagnosed thyroid condition before their crisis. The most common scenario is not that the disease was unknown but that treatment lapsed. Patients stop taking levothyroxine because they feel fine, because they lose access to healthcare, because they develop another illness that disrupts their routine, or because they simply forget over time. Hypothyroidism without treatment is often a slow, insidious deterioration: people adapt to feeling sluggish, cold, and foggy over months or years, and the urgency of daily medication can feel abstract when the consequences are not immediately dramatic.
Elderly patients living alone are particularly vulnerable. Cognitive decline from the hypothyroidism itself can erode medication adherence, creating a self-reinforcing loop. A winter illness like pneumonia or a fall that sends someone to the hospital can then act as the precipitant, and if the admitting team does not check thyroid function or recognize the clinical signs, the window for intervention narrows quickly. For anyone with a hypothyroid family member, especially an older adult, the practical takeaway is straightforward: consistent thyroid medication adherence matters far more than it might appear, and any acute illness in a hypothyroid person warrants attention to whether their thyroid treatment has been maintained.